After a subdued start to the year, PE healthcare services investing in Q3 2024 showed early signs of a rebound. Despite a modest dip in deal volume from Q2, with 148 deals announced or closed, investor confidence is slowly returning. Much of the activity focused on...
What a difference a year makes. In the first half of 2024, the MedTech sector showed a notable uptick in M&A activity, with 114 acquisitions valued at $40.3 billion — close to last year’s total. Despite fewer venture rounds, funding remained strong at $9.7...
The JPM Q1 2024 MedTech Licensing and Venture report highlights the first quarter of 2024 and shows promising developments in the MedTech investment landscape. There are indications of a potential recovery and growth compared to previous years. Can we be so lucky?...
Healthcare PE activity in Q1 2024 remained subdued, marking a continuation of the downturn seen in 2023. PE sponsors announced or closed an estimated 158 deals in the quarter, maintaining the sluggish pace of 2023. Despite a somewhat more optimistic narrative around...
A few weeks ago, McDermott + Bull Interim Leaders and I hosted a small breakfast for C-Level executives in the life sciences sector. Simon Arkell, CEO and Co-Founder of Ryght AI, joined us as our keynote speaker to share his thoughts and insights on AI and its impact...
Recently, my colleague Mark McConnell and I hosted a breakfast meeting with around 40 local C-Suite executives within the life sciences sector. Paul LaViollette, Managing Partner and Chief Operating Officer of SV Health Investors, joined us from Boston to share his...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Privacy policyOkNo
